Ascentage Pharma Group Corporation

New clinical data for Ascentage’s lisaftoclax support its further development in combination with azacitidine for acute myeloid leukemia (AML) or high-risk myelodysplastic syndromes (HR-MDS), the Chin

There were six initial public offerings by biopharmaceutical companies on Western stock exchanges during the first quarter of 2025, up from four in the fourth quarter of 2024, but all of the IPOs occu

Jiangsu Hengrui Pharmaceuticals, China’s top innovative drug maker by pipeline size, is set to spring back into the high-stakes arena of global Phase III clinical trials which include sites in the US

Sionna Therapeutics has multiple drug candidates in the clinic and an ambition to improve cystic fibrosis treatment beyond what Vertex Therapeutics has achieved with its blockbuster portfolio of cysti